Table 4.
Adjusted risk at 30 days for non-survivors and survivors among non-hospitalized SARS-CoV-2-positive veterans by indicated post-index medication use and race.
| Post-Index | Non Survivors ^ |
Survivors ^ | Multiplicity Corrected ‡ | ||
|---|---|---|---|---|---|
| Medication * | n (%) | n (%) | aRR (95%CI) † | p-Value | |
| Black (N = 6534) | |||||
| Vitamin D | Corticosteroids | ||||
| − | + | 16 (12) | 811 (13) | 1.0 Referent | --- |
| − | − | 116 (85) | 5293 (83) | 1.2 (0.68–2.0) | 0.56 |
| + | + | 0 (0) | 54 (<1) | ∞ | ∞ |
| + | − | 5 (4) | 239 (4) | 0.93 (0.24–3.6) | 0.92 |
| White (N = 11,365) | |||||
| Vitamin D | Corticosteroids | ||||
| − | + | 51 (15) | 1233 (11) | 1.0 Referent | --- |
| − | − | 284 (82) | 9448 (86) | 0.86 (0.42–1.7) | 0.67 |
| + | + | 6 (2) | 56 (1) | 2.7 (0.77–9.2) | 0.12 |
| + | − | 6 (2) | 281 (3) | 0.35 (0.10–1.2) | 0.093 |
^ Non-referent group of the indicated comparison factor. * Systemic administration by mouth or intramuscular injection. † Adjusted for Age (≤60, 61–70, 71–80, >80), Alcohol Use Disorder (Yes, No), BMI (<18.5, 18.5–24.9, 25–29.9, ≥30), Charlson Comorbidity Index (0, 1–2, 3–4, 5+), Current Smoker (Yes, No), Location (Pacific-Mountain, Mid-West/Continental, East Coast), Sex (Male, Female), and Time (March, April–September). ‡ Subset analyses corrected for multiplicity using the Hochberg step-up procedure for multinomial comparisons. ∞ = non-convergent (zero cell). aRR = Adjusted relative risk; BMI = body mass index (kg/m2); CI = confidence interval.